---
title: 'Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged
  lung adenocarcinoma: a case report'
date: '2024-12-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39688636/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241218172032&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Progressive leptomeningeal metastases (LM) are associated with intractable
  neurological symptoms and a poor prognosis, and effective treatment options are
  limited. Intrathecal (IT) pemetrexed has been shown to confer clinical benefit in
  lung adenocarcinoma, yet our understanding of the efficacy and safety of the treatment
  is limited. We report a patient with a long-standing history of leptomeningeal disease
  due to ALK-positive adenocarcinoma of the lung, previously controlled by increased
  ...
disable_comments: true
---
Progressive leptomeningeal metastases (LM) are associated with intractable neurological symptoms and a poor prognosis, and effective treatment options are limited. Intrathecal (IT) pemetrexed has been shown to confer clinical benefit in lung adenocarcinoma, yet our understanding of the efficacy and safety of the treatment is limited. We report a patient with a long-standing history of leptomeningeal disease due to ALK-positive adenocarcinoma of the lung, previously controlled by increased ...